Core Viewpoint - The article highlights the prescription of Seladelpar, a drug for primary biliary cholangitis (PBC), as the first in mainland China, benefiting from a temporary import policy for rare disease medications in Beijing [1] Group 1: Drug Information - Seladelpar is a potent and selective PPARδ agonist that effectively improves cholestasis, reduces liver inflammation and fibrosis, and enhances symptoms and prognosis for PBC patients [1] - The drug is expected to be launched in the United States in August 2024 and in the European Union in February 2025 [1] Group 2: Policy Impact - The prescription of Seladelpar was made possible due to the policy advantages of the Tianzhu Rare Disease Guarantee Pilot Zone, allowing for rapid approval and access to cutting-edge treatments for PBC patients in need [1]